Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Amazon launches fixed pricing to treat conditions like hair loss. Hims & Hers stock drops 15%
10:26am, Thursday, 14'th Nov 2024
Amazon announced Prime members can access new upfront pricing to treat five common conditions like erectile dysfunction and men's hair loss. The move places the company in competition with other direc
Telehealth firm Hims & Hers launches weight-loss drug shortage tracker
12:17pm, Wednesday, 13'th Nov 2024
Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's Weg
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
11:30am, Wednesday, 13'th Nov 2024
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
SHOP, CVNA, HIMS Highlight Strength & Diversity in Consumer Discretionary
11:35am, Tuesday, 12'th Nov 2024
Shopify's (SHOP) massive pop after earnings is just the latest flex of Consumer Discretionary's strength, according to Roxanna Islam. The sector has grown 20% year-to-date compared to Consumer Staples
Up 298% in a Year, Is Hims & Hers Health Still a Buy?
09:13am, Tuesday, 12'th Nov 2024
The healthcare company is on fire, and it's still cheap by many measures.
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance
08:00am, Tuesday, 12'th Nov 2024
Every earnings season has its share of outperformers, companies that report blowout quarters and raise their forecasts. The market reacts quickly sending shares sharply higher.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Monday, 11'th Nov 2024
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Undeservedly Undervalued
10:00am, Saturday, 09'th Nov 2024
H&H's strong Q3 results signals a fundamental shift in the healthcare industry. GLP-1 drugs are certainly a growth catalyst for H&H but it is just a tiny component of the overall investment thesis. H&
Hims & Hers: A High-Growth Gem On The Verge Of Big Upside
03:52pm, Friday, 08'th Nov 2024
Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported a 77% year-over-year revenue growth, with a subscriber base of 2 million. H
Earnings Estimates Moving Higher for Hims & Hers Health (HIMS): Time to Buy?
01:21pm, Friday, 08'th Nov 2024
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
After Another Blowout Quarter of Surging Revenue, Is Hims & Hers Stock a Once-in-a-Decade Buy?
04:20am, Friday, 08'th Nov 2024
Hims & Hers strong performance involves much more than just GLP-1 drugs.
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
12:36pm, Wednesday, 06'th Nov 2024
The company expects to enjoy many GLP-1 tailwinds in 2025.
Hims & Hers: Why This Healthcare Stock's Growth Makes It a Buy
08:21am, Wednesday, 06'th Nov 2024
Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, thin
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
04:31pm, Tuesday, 05'th Nov 2024
Hims & Hers Health (HIMS) reported third-quarter results that topped analysts' expectations Monday, lifting its shares, as the company said t plans to release a generic version of a Novo Nordisk (NVO)
Hims & Hers Health CFO talks GLP-1s, earnings
11:20am, Tuesday, 05'th Nov 2024
Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, help
